Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock

Stock Information for Neos Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Neos Therapeutics Inc.

Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScience
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScience
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - CPAH, UROV, ANH, CGIX, CBLI, NEOS
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Neos Therapeutics, Inc. - NEOS
Moore Kuehn Encourages MTSC, SPRQ, NEOS, and PRSP Investors to Contact Law Firm
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PS, BEAT, HCAP, NEOS, HBAN

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.